Companion Dx poised to soar around the globe; Medtronic expands stent indications in Europe;

 @FierceMedDev: Spiking costs blunt Covidien's strong sales quarter. News | Follow @FierceMedDev

 @DamianFierce: Dx company LipoScience is going public, targeting a $40M IPO as $LPDX. Report | Follow @DamianFierce

> The global market for companion diagnostics will reach $19.3 billion by 2023, according to an analyst report. More

> Molecular diagnostic outfit Transgenomic has raised another $8.3 million in private placement financing, planning to speed the commercialization of its genetic tests. News

> Medtronic ($MDT) has picked up CE marks for its Complete SE stent, clearing the device for use in the superficial femoral arteries and proximal popliteal arteries. Item

> Stryker ($SYK) executives told investors that the company's pending $764 million buyout of Trauson Holdings is key to its future growth. Article

> Artemis Diagnostics is changing its name to Lightpoint Medical as it moves forward with a molecular imaging technology for cancer surgery. Release

Biotech News

 @FierceBiotech: AstraZeneca kicks tires on respiratory program ditched by J&J. Story | Follow @FierceBiotech

@JohnCFierce: Cowen's Ed Nash is predicting '16 arrival of Sarepta's eteplirsen, with $263M start Question about accelerated OK. Personally I'm doubtful. | Follow @JohnCFierce

@RyanMFierce: IBM touts push into #biotech with bug-busting gel. Should we care yet? Report | Follow @RyanMFierce

> Celsion snags up to $100M Chinese pharma tie-up ahead of PhIII cancer data. Article

> What's in a drug name? Hopefully some Xzitement. News

Pharma News

@FiercePharma: Merrill Lynch high on Bayer: The company made its list of top Euro-stocks, thanks to new drugs/pipeline. More | Follow @FiercePharma

 @AlisonBFierce: Feds OK Novavax's experimental flu vaccine program. News | Follow @AlisonBFierce

> Groups lobby White House as sunshine rule lingers. Report

> Novartis faces probes on Tekturna tactics, Iran sales. News

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.